OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.

Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models, including mouse xenografts. AD80 is highly active in a tumor xenograft model. Experimental dosing for AD80 was determined from maximum tolerated dosage (MTD) studies and pharmacokinetic (PK) analysis. Quantities of AD80 in blood plasma were determined by LC-MS/MS at Medicilon.

8ÔÂ21ÈÕ,×ðÁú¿­Ê±ÌØÑûÒ©Îï´úл¶¯Á¦Ñ§²¿DMPK¸±Ö÷ÈÎ Íòßäßä×ö¿ÍÔÆ¿ÎÌÃ
£¬´øÀ´Ö±²¥¡¶LC-MS/MSÊÖÒÕÔڹѺËÜÕËáÀàÒ©ÎïÉúÎïÆÊÎöÖеÄÓ¦ÓÃ̽Ë÷ÓëʵսսÂÔ¡·